Black technology, starting from daily check-in

Running all the way to the living room, Lin Yu didn't think much, just picked up his mobile phone, and checked the details about the five-year-old boy's terminal cancer on Weibo.

Soon, Lin Yu understood all the ins and outs of the whole thing.

However, when Lin Yu learned that this five-year-old boy named Xiao Yi had advanced neuroblastoma cancer, he couldn't help frowning.

Because of what he has learned.In this 18-year parallel world, China, there is no immunotherapy for cancer in terms of solid tumors.

You should know that cancer immunotherapy is a new type of treatment that has emerged after surgery, chemotherapy, radiotherapy and targeted therapy. It is called the "fifth major therapy" for cancer treatment. cancer.

Not to mention China, even the top medical companies in the United States are still conducting various explorations and preliminary experiments on cancer immunotherapy.

Therefore, all hospitals now use traditional treatment methods to treat cancer,

But these traditional treatment methods are basically useless to Xiaoyi, who is currently in the advanced stage of cancer, except to prolong his life cycle a little.

The CAR-T cell immunotherapy obtained by Lin Yu from the system, although it can act on both solid tumors and non-solid tumors, it also has limitations, and it only targets hematological tumors.

In other words, the therapeutic effect of the "Bai Ze" inhibitor is only aimed at all non-solid tumors in terms of hematological tumors.

However, CAR-T cell immunotherapy is effective for all solid tumors and non-solid tumors in hematological tumors, and the effect is very abnormal.

You must know that there are hundreds of cancers in blood cancers. Generally speaking, several cancers correspond to a unique targeted drug.

The CAR-T cell immunotherapy that can be rewarded by the system can take effect on all of these hundreds of cancers. One can imagine how powerful it is.

However, such a powerful CAR-T cell immunotherapy has no solution for neuroblastoma.

Because it does not belong to the category of hematological tumors, but belongs to neuroendocrine tumors, CAR-T cells can't do anything about it.

Therefore, if you want to treat Xiaoyi's neuroblastoma, you can only reinvent a new cancer immunotherapy that is specifically aimed at neuroendocrine tumors.

Thinking of this, Lin Yu couldn't help but breathe a sigh of relief, and immediately, a trace of determination passed through his eyes.

Although he did not obtain the technology on neuroma treatment from the system, he can fully rely on the super brain's god-level skills to carry out the research and development of neuroma immunotherapy using CAR-T cell immunotherapy as an example.

Although he doesn't know whether he, who has turned on the Ultrain, can find a targeted drug specifically for neuroma in a short period of time and make it.

However, this time, he just wanted to try his best and give it a try without leaving any regrets!

After making up his mind, Lin Yu, who knew that time was running out, quickly started to act. He immediately called Ouyang Lei, the CEO of Baiji Company, and asked him to prepare relevant equipment and lead a professional neuroma medical team in the immuno-oncology clinic. The R&D center is waiting for itself.

After finishing speaking, Lin Yu quickly put on his clothes, pants and shoes, and after a brief talk with Su Muyun, under the latter's gentle and considerate gaze, he went downstairs and drove towards Baiji Company at a high speed.

As for the comments left by many netizens on his message board on Weibo, Lin Yu has no time to reply.

Just when Su Muyun was standing at the window of her house, watching Lin Yu drive away, Su Muxin also just came out of the room.

"Sister, what are you looking at?"

While Su Muxin was talking, she walked over curiously, stood beside her, and put her little head out of the window.

Looking here and there for a while, she didn't find anything special. Su Muxin couldn't help curling her lips, and immediately retracted her small head, looked at Su Muyun, and said pitifully, "Sister, I'm hungry, why don't you go Urge brother-in-law to cook, it's already 05:30."

Su Muyun glanced at her lightly, and said: "Your brother-in-law just went out on a temporary basis, and he probably won't be back until tomorrow. It's probably impossible for you to ask him to cook dinner."

Hearing this news, Su Muxin was stunned for a moment, then she came back to look at her, and smiled: "Since brother-in-law is busy, when will you make dinner?"

"Don't do it, you can order takeaway, and order one for me by the way."

Seeing Lin Yu driving the car completely disappear from his sight, Su Muyun turned around and walked towards the live broadcast bedroom without looking back.

Su Muxin: "???"

Good guy, if the uncle doesn't come back, he won't even make dinner.

You don't treat me like a human being at all.

He really deserves to be his sister!

After Su Muxin sighed helplessly, she finally put on a bitter face, took out her mobile phone and started ordering takeaway, forced to accept this sad reality.

at the same time.

Half an hour later, Lin Yu stopped in the courtyard of the Immuno-oncology R&D Center of Baiji Company.

After seeing him get off the car, Ouyang Lei and Eric, the person in charge of the Immuno-Oncology R&D Center, who had been waiting for a long time, rushed to greet him.

"Chairman, the neuroma professional team you want is already waiting for you in the GMP laboratory."

While talking, Ouyang Lei introduced to Lin Yu: "By the way, this is the person in charge of the Immuno-Oncology Research and Development Center, Eric, we met at dinner before, if you have any needs next, please let me know You can talk to him."

"Well, hello, Eric, I'll trouble you later."

Lin Yu nodded, then smiled and looked at the blond-haired, middle-aged foreigner next to him,

"Where, it is our honor that the chairman can come to our immuno-oncology research and development center."

Eric just smiled modestly, and immediately looked at Lin Yu with fiery eyes: "Excuse me for asking, I wonder if the chairman is here today to develop immunotherapy for neuroma?"

Since Xiaoyi's incident on the Internet has become known all over the Internet, many people have been paying attention, even him.

Listening to Eric's words without any translation accent, Lin Yu glanced at him in surprise, then shook his head and said: "I don't have any specific ideas yet, and I need to verify my ideas one by one later, So I don’t know if it will be successful or not.”

Regarding the uncertainty in Lin Yu's words, Ouyang Lei patted Eric on the shoulder with a smile on his face, and said meaningfully: "The chairman comes to verify the idea every time, but it turns out that the research and development is successful every time. , so you know."

Hearing this, a smile of enlightenment appeared on Eric's face.

It turns out that the chairman is not really ignorant, but is being modest.

Possessing such a rare noble quality at such a young age is indeed a dragon among men.

Thinking of this, Eric looked at Lin Yu with admiration in his eyes.

Lin Yu: "..."

Looking at the "I understand" smiles of the two people in front of him, Lin Yu was speechless for a while.

Why doesn't anyone believe him every time he tells the truth?

Moreover, I really don't know this time.

Sighing helplessly, Lin Yu was too lazy to talk to them, and walked directly to the R&D center.

Seeing this, Ouyang Lei and Eric also followed with smiles on their faces.

Along the way, Lin Yu felt a little unconfident about the confident smiles of the two of them, which had been developed by neuroma immunotherapy.

Soon, the three came outside the GMP laboratory.

Because of non-professionals, Ouyang Lei didn't go in. Only Lin Yu and Eric put on white masks and changed into white work clothes to go in.

However, before going in, Lin Yu had told Ouyang Lei in advance that the research and development time this time might take a long time, and he could go back early if he couldn't hold on.

Regarding this, Ouyang Lei just waved his hands indifferently.

In his heart, Lin Yu's research time is only one night at most, how could he not be able to hold on.

When Lin Yu walked into the GMP laboratory, a professional team of 30 people was already waiting for him there.

Neuroblastoma and other related experimental samples and tools have also been prepared.

Seeing this, Lin Yu didn't talk nonsense, and directly activated the super brain skills without hesitation.

With the opening of Ultrain, the knowledge points about tumor immunotherapy in Lin Yu's mind began to be based on CAR-T cell immunotherapy, and countless new ideas and ideas continued to burst out.

While deducing the feasibility of countless ideas in his mind, Lin Yu began to command in an orderly manner.

"From now on, you will form a team by yourself, in groups of five, and use high concentrations of IL-2 to activate the donor's peripheral blood mononuclear cells."

"People in the second group, lymphocytes were isolated from resected tumor tissue or cancerous pleural ascites, activated and expanded by IL-2 in vitro."

"Three groups of people mixed DC cells and CIK cells to observe whether they could regulate each other, so as to achieve the purpose of increasing cytokine release and enhancing cytotoxicity."

"People in the four groups used gene editing technology to integrate and express a gene for interleukin 12 factor (L12) for me, and let interleukin 12 be locally expressed at the targeted position."

.........

As one order after another came out of Lin Yu's mouth, the [-] professional teams also started to operate quickly, devoting themselves to the research.

Even Eric, who was watching the show, was no exception, and quickly joined their busy team.

After Lin Yu issued the order, he also devoted himself to the research and development of the most core technology, constantly looking for antibodies against neuroblastoma.

Generally speaking, cancers with solid tumors can be said to be several times more severe than cancers with non-solid tumors.

Because solid tumors can form a microenvironment in patients with infiltrating regulatory T cells, tumor-associated macrophages, high expression of PD-1, and inhibitory cytokines.

They protect the tumor very tightly, just like a fully armed fortress, and targeted drugs can't act inside at all, so the therapeutic effect is very weak.

Non-solid tumors are relatively simple, because they have no fortresses, so as long as they find specialized antibodies, they can directly strike them with precision.

After four hours, all but the fourth group of ideas among the six groups had failed.

Even Lin Yu did not find a specific antibody for neuroblastoma.

However, they are not without gains, because they know that the fourth integrated expression of the interleukin 12 gene can improve the microenvironment of immunotherapy.

That is to say, this interleukin 12 gene can summon nearby NK cells to activate, and wake up the function of infiltrating T cells, assisting CAR-T cells to kill target-negative and positive cells of solid tumors.

This is equivalent to the defense bastion that can directly penetrate solid tumors.

But unfortunately, this is only to break through the fortress, and it cannot eliminate the neuroblastoma inside.

Because they lack antibodies that specifically target it.

For this achievement, except for Lin Yu, everyone else is a little excited.

Because in such a short period of time, they have already broken through a technical problem of tumor immunity.

For them, this is simply great news.

Soon, after a brief disappointment, Lin Yu let out a sigh of relief, adjusted his mentality, and kept reflecting on the series of orders just issued, looking for what went wrong.

Soon, he found out why.

That is, he seems to have reversed the priority, because he subconsciously focuses on CAR-T cell immunotherapy, supplemented by neuroma knowledge points to think about the problem.

Since it is a cancer of neuroma, how can he use the method of blood tumor as the main method?

Thinking of this, Lin Yu's eyes brightened instantly, and he began to learn the lessons of the failure just now, focusing on the knowledge points of neuroma, and constantly began to deduce its derivative ideas and ideas.

Soon, with countless thoughts gushing out, Lin Yu continued to direct everyone to start new research.

What excited Lin Yu was that this time he found a large number of antigens on the outer membrane of neuroblastoma - GD2!

This means that his idea is not wrong, he can directly make antibodies against the target of GD2.

Five hours later, Lin Yu combined with granulocyte-macrophage colony-stimulating factor to produce the first antibody specifically targeting neuroblastoma.

However, the objective response rate (ORR) of this antibody only reached 45%.

In addition, good news also came from those six groups.

The fourth group found that GD2 targeting can be combined with CAR-T cell immunotherapy.

This can not only improve the ability to recruit T cells, but also reduce the risk of non-specific T cell participation and reduce the occurrence of side effects.

This is undoubtedly the second way out that can be used as a neuroblastoma antibody.

Three hours later, Lin Yu used the GD2 and CART cell combination method discovered by the fourth group to successfully combine T cells with antibodies in Bie format!

Moreover, the objective response rate (ORR) of this antibody reached an astonishing 78%!

As of six o'clock in the morning the next morning, that is, now, they have found two antibodies against neuroblastoma!

For this unexpected result, Lin Yu finally showed a satisfied smile.

Immediately, after six hours of struggle in the morning, Lin Yu combined the two antibodies, took the essence and discarded the dross.

In the end, he found a brand new antibody that still focuses on CAR-T cell immunotherapy but targets neuroblastoma!

And the remission rate of this new antibody reached a terrifying 95%!

After the news came out, all the researchers in the entire laboratory, who had worked hard all day and night, all had red eyes, embraced each other excitedly, cheered and jumped, very excited.

And this move immediately woke up Ouyang Lei who was dozing outside the door.

After seeing this scene, a smile of "I knew it" appeared on his face.

……